Friday, November 17, 2023
Print Current Session:
![]() |
|
Friday
SESSION 93:
NEW DEVELOPMENTS IN MEDICAL AND DRUG TREATMENTS: BEST ANTIPLATELET REGIMENS; UPDATE ON RARE VASCULAR DISEASES
Location: Grand Ballroom West, 3rd Floor
Moderators:Caron B. Rockman, MD / James H. Black, III, M.D. |
|
SESSION 93 SCHEDULE | |
ANTIPLATELET REGIMENS | |
2:36 PM - 2:41 PM | Optimal Antiplatelet Management With CEAs, Lower Extremity Bypasses And Open AAA Repairs |
Presenter(s):David H. Stone, MD Location: Grand Ballroom West, 3rd Floor |
|
2:42 PM - 2:47 PM | Current Optimal Anticoagulation And Antiplatelet Treatment For High Risk Lower Extremity Bypasses – Vein And PTFE: How Are DOACs Useful |
Presenter(s):Peter Henke, MD Location: Grand Ballroom West, 3rd Floor |
|
2:48 PM - 2:53 PM | What Is The Best Medical Treatment After Carotid, Aortic And Lower Extremity Endovascular Treatments |
Presenter(s):Maciej L. Dryjski , MD, PhD Location: Grand Ballroom West, 3rd Floor |
|
2:54 PM - 2:59 PM | Why Clopidogrel Is Effective In <50% Of Patients At Standard Doses: How To Identify And Fix This Problem |
Presenter(s):Karthik Kasirajan, MD Location: Grand Ballroom West, 3rd Floor |
|
NEW DEVELOPMENTS IN LIPID MANAGEMENT – STATINS | |
3:00 PM - 3:05 PM | Safety And Benefit Of Statins And Medical Treatment In Vascular Patients: Why These Treatments Are Underutilized – Especially In Women: Statin Intolerance Has Been Over Emphasized: LDL-C Should Be Monitored And Treated To An Optimal Level |
Presenter(s):Christian A. Behrendt, MD Location: Grand Ballroom West, 3rd Floor |
|
3:06 PM - 3:11 PM | The Importance Of Lipoprotein Little a [Lp(a)] Levels In Determining Atherosclerotic Risk: When Should It Be Measured And If High, How Treated: Do PCSK-9 Inhibitors Help: Will An Oral PCSK-9 Inhibitor Be Available |
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC Location: Grand Ballroom West, 3rd Floor |
|
3:12 PM - 3:17 PM | Lowering LDL-C And Controlling Elevated Blood Pressure Can Lower Cardiovascular Risk 80%: What To Do If Patients Can’t Tolerate A Statin Dose: Ezetimide, (Zetia), A PCSK9 Inhibitor, Inclisiran, Bempedoic Acid (Nexletol) |
Presenter(s):Richard Bulbulia, MA, MD, FRCS Location: Grand Ballroom West, 3rd Floor |
|
3:18 PM - 3:23 PM | Value And Limitations Of Statins And Non-Statin Lipid Lowering Agents In Patients With Carotid Artery Stenosis |
Presenter(s):Kosmas I. Paraskevas, MD Location: Grand Ballroom West, 3rd Floor |
|
3:24 PM - 3:32 PM | Panel Discussion |
3:32 PM - 3:37 PM | Diagnosis And Treatment Of Buerger’s Disease In 2023: Does It Exist Or Is It Just A Variant Of Atherosclerosis |
Presenter(s):Kamphol Laohapensang, MD Location: Grand Ballroom West, 3rd Floor |
|
3:38 PM - 3:43 PM | How To Make Operations For Complications Of Vascular Ehlers Danlos Syndrome Go Well |
Presenter(s):James H. Black, III, M.D. Location: Grand Ballroom West, 3rd Floor |
|
3:44 PM - 3:49 PM | Medical Treatment Of Patients With Vascular Ehlers Danlos Syndrome: How Does Celiprolol Treatment Work And How Does It Help |
Presenter(s):Martin Björck, MD, PhD Location: Grand Ballroom West, 3rd Floor |
|
3:50 PM - 3:55 PM | TBD |
3:56 PM - 4:00 PM | Panel Discussion |
END OF SESSION 93 | |
previous | next |